Related Experiment Video
Updated: Jun 29, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Precision Endpoints for Contemporary Precision Oncology Trials
Regina Hoo1,2,3, Kevin L M Chua4,5, Pankaj Kumar Panda6
1Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
Summary:
Traditional endpoints such as progression-free survival and overall survival do not fully capture the pharmacologic and pharmacodynamic effects of a therapeutic intervention. Incorporating mechanism-driven biomarkers and validated surrogate proximal endpoints can provide orthogonal readouts of anti-tumor activity and delineate the relative contribution of treatment components on an individual level, highlighting the limitation of solely relying on aggregated readouts from clinical trials to facilitate go/no-go decisions for precision therapies.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
07:03Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
Published on: December 1, 2023